[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 679 Introduced in House (IH)]

<DOC>






119th CONGRESS
  1st Session
                                H. R. 679

 To nullify the modifications made by the Food and Drug Administration 
in January 2023 to the risk evaluation and mitigation strategy for the 
          abortion pill mifepristone, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            January 23, 2025

  Mrs. Harshbarger (for herself, Mr. Hern of Oklahoma, Mr. Bost, Mrs. 
 Miller of Illinois, Mr. Weber of Texas, Mr. Babin, Mr. Moolenaar, Mr. 
Webster of Florida, Mr. Baird, Mr. Higgins of Louisiana, Mr. Feenstra, 
Mr. Yakym, Mr. Biggs of Arizona, Mr. Palmer, and Mr. Guest) introduced 
 the following bill; which was referred to the Committee on Energy and 
                                Commerce

_______________________________________________________________________

                                 A BILL


 
 To nullify the modifications made by the Food and Drug Administration 
in January 2023 to the risk evaluation and mitigation strategy for the 
          abortion pill mifepristone, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. NULLIFICATION OF MODIFICATIONS TO REMS FOR MIFEPRISTONE.

    (a) Nullification.--The modifications made by the Food and Drug 
Administration in January 2023 to the risk evaluation and mitigation 
strategy under section 505-1 of the Federal Food, Drug, and Cosmetic 
Act (21 U.S.C. 355-1) for mifepristone are hereby nullified.
    (b) No Substantially Similar Provisions.--The Secretary of Health 
and Human Services (or any head of any office, department, or agency of 
the Department of Health and Human Services) shall not establish, 
implement, or enforce any provision of a risk evaluation and mitigation 
strategy under section 505-1 of the Federal Food, Drug, and Cosmetic 
Act (21 U.S.C. 355-1) for mifepristone that is substantially similar to 
any of the modifications nullified by subsection (a).
                                 <all>